Non-coating anti-microbial, anti-host protein deposition, anti-inflammatory urinary catheter
Non-coating anti-microbial, anti-host protein deposition, anti-inflammatory urinary catheter
批准号:
10697567
负责人:
Marc D. Hein
金额:
$32.5万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-06-05 至 2025-05-31
关键词:
AddressAdhesionsAdoptedAdsorptionAnti-Bacterial AgentsAnti-Inflammatory AgentsAntimicrobial ResistanceAttentionAutomobile DrivingAwarenessBiocideBladder ControlCategoriesCathetersChemistryClinical TrialsComplexDepositionDevelopmentEffectivenessElectrostaticsEventGenerationsHealthHumanHydration statusHydrogelsIn VitroInfectionInfection ControlInflammationLearningManufacturerMarket ResearchMeasurableMedical Care CostsMethodsMicrobeMicrobial BiofilmsModelingMusOutcomePatientsPhasePlant ResinsPolymersPreventionPrimary Health CareProliferatingProteinsReactionRecording of previous eventsResearchResearch PersonnelResistanceRiskRouteRubberSafetySiliconSilicone ElastomersSiliconesSilverSkilled Nursing FacilitiesSurfaceTechnologyTestingThickToxic effectTubeUropathogenWaterabsorptionantimicrobialantimicrobial drugbiomaterial compatibilitycatheter associated UTIcommercial applicationcopolymercostcost effectivedosagedrug resistant pathogenhealthcare-associated infectionsimmunoreactionin vivoin vivo evaluationinventionirritationmicroorganismmonomernext generationpathogenpreventsafety testingsuccessurinary
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Abstract: Catheter-associated urinary tract infection (CAUTI) is the most common type of
healthcare-associated infection, however currently there is no effective technology to address
the problem. Antimicrobial (anti-biofilm) functionality on the catheter surface is an important field
that has gained a lot of attention; however, commercial applications are limited due to a lack of
infection control outcomes (silver-hydrogel coating) or irritation/discomfort (nitrofural) in clinical
trials. Recent research has now shown that biofilm formation is caused by protein deposition
which will also cause inflammation and immunoreaction. Therefore, the next generation
technology needs both antimicrobial functionalities along with anti-immunoreaction capabilities
to produce a compound effect for infection control. Our company invented a new category of
polymer additive product (HaloAddTM) that can be cost-effectively blended into existing silicon
rubber resins to produce silicone urinary catheters that can provide multiple functions such as
antimicrobial, anti-protein adhesion and anti-inflammation. This phase I effort is geared towards
answering some basic feasibility, efficacy, and safety questions about this approach using both
in vitro and in vivo testing methods. We propose three specific aims:
1) optimize polymer
synthesis and blending parameters to develop HaloAdd-blended silicone rubber formulas with
maximum antimicrobial and anti-fouling efficacy; 2) determine uropathogen attachment
prevention, biocompatibility, and stability of HaloAdd-blended silicone tubes; 3) demonstrate in
vivo that HaloAdd catheter provides measurable anti-inflammation and anti-biofilm outcomes in
a mouse infection model. Success with this phase I effort will lay the groundwork for FDA
clearance for human trials.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金